Therapeutic Class Overview: Newer Oral Anti Androgens – Expanding Role in the treatment Paradigm of Prostate Cancer

Published: February 2014
No. of Pages: 44
    ReportsandReports

This report is available at 15% Discount till 31st Jan 2017. To avail discount please contact at +1-888-391-5441 / sales@reportsandreports.com.


XTANDI (Enzalutamide) – Does it have potential to compete against ARN-509 in earlier setting?

Zytiga (Abiraterone Acetate) – Ongoing Combination trials creates potential beyond Patent Expiry

In recent past approval and launch of various newer treatment options like Xtandi (Enzalutamide, Astellas/Medivation), Zytiga (Abiraterone acetate, JNJ), Jevtana (Cabazitaxel, Sanofi), & Xofigo (radium Ra 223, Boehringer Ingelheim) has evolved the treatment paradigm of treating late stage prostate cancer. In coming years, we expect this to repeat in early stage prostate cancer treatment (nmCRPC, before Prostectomy) due to launch of newer antiandrogens in this setting.  Longer duration of therapy and high prevalence makes this earlier setting market more lucrative and bigger for newer options than late stage if they succeed.

In coming years, we expect second generation antiandrogens (Androgen synthesis inhibitors/Androgen receptor inhibitors, Xtandi, ARN-509, ODM-021, Zytiga, TAK-700, TOK-001) to replace them and expand their use beyond current levels in nmCRPC (non metastatic Castrate resistance Prostate cancer) patients and also in pre-prostectomy (Chart 3).  This newer agents will expand these markets atleast by $10b ($6b in pre prostectomy, $4b nmCRPC) if get success.

TAK-700 (Takeda), ARN-509 (JNJ) and Xtandi are strong candidates to get success in early stage prostate cancer and in next two years PhIII clinical data from EL-04, PROSPER and SPARTAN study, will decide who will lead this market.  While TAK-700 has a first launch advantage it is important to see how ARN-509, compete to Xtandi in earlier setting and in terms of safety for penetrating in early prostate cancer market.  Other than these PhIII studies, Xtandi PhII data from neoadjuvant PC and ARN-509 data in preprostectomy patients will decide their use in earlier setting. We estimate $2.8b peak sales for Xtandi in mCRPC setting, while in earlier setting it has potential to generate atleast ~$2b if it gets success in PROSPER , STRIVE, TERRAIN and neoadjuvant study.

Published By: MP Advisors
Product Code: MP Advisors21


Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and well share relevant market report titles for you to explore.

Related Reports:

  • China Testosterone Propionate Market Research Report 2017

    Notes: Sales, means the sales volume of Testosterone Propionate Revenue, means the sales value of Testosterone Propionate This report studies Testosterone Propionate in China market, focuses on the top players in China market, with capacity, pro...

  • China Dystonia Drug Market Research Report 2017

    Notes: Sales, means the sales volume of Dystonia Drug Revenue, means the sales value of Dystonia Drug This report studies Dystonia Drug in China market, focuses on the top players in China market, with capacity, production, price, revenue and ma...

  • China DHA Soft Capsule Market Research Report 2017

    Notes: Sales, means the sales volume of DHA Soft Capsule Revenue, means the sales value of DHA Soft Capsule This report studies DHA Soft Capsule in China market, focuses on the top players in China market, with capacity, production, price, reven...

  • China DHA Algae Oil Market Research Report 2017

    Notes: Sales, means the sales volume of DHA Algae Oil Revenue, means the sales value of DHA Algae Oil This report studies DHA Algae Oil in China market, focuses on the top players in China market, with capacity, production, price, revenue and ma...

  • China Dermatology Drug Market Research Report 2017

    Notes: Sales, means the sales volume of Dermatology Drug Revenue, means the sales value of Dermatology Drug This report studies Dermatology Drug in China market, focuses on the top players in China market, with capacity, production, price, reven...

  • China Ceramide Market Research Report 2017

    Notes: Sales, means the sales volume of Ceramide Revenue, means the sales value of Ceramide This report studies Ceramide in China market, focuses on the top players in China market, with capacity, production, price, revenue and market share for ...

  • China Amlodipine Besylater Market Research Report 2017

    Notes: Sales, means the sales volume of Amlodipine Besylater Revenue, means the sales value of Amlodipine Besylater This report studies Amlodipine Besylater in China market, focuses on the top players in China market, with capacity, production, ...

  • Europe Monoclonal Antibody Market Report 2017

    Notes: Sales, means the sales volume of Monoclonal Antibody Revenue, means the sales value of Monoclonal Antibody This report studies sales (consumption) of Monoclonal Antibody in Europe market, especially in Germany, France, UK, Russia, Italy, ...

  • United States Veterinary/Animal Vaccines Market Report 2017

    Notes: Sales, means the sales volume of Veterinary Animal Vaccines Revenue, means the sales value of Veterinary Animal Vaccines This report studies sales (consumption) of Veterinary Animal Vaccines in United States market, focuses on the top pla...

  • United States Eubiotics Market Report 2017

    Notes: Sales, means the sales volume of Eubiotics Revenue, means the sales value of Eubiotics This report studies sales (consumption) of Eubiotics in United States market, focuses on the top players, with sales, price, revenue and market share f...


Why ReportsnReports.com?

  • 500,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: sales@reportsandreports.com Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Consumer Goods market as per your needs. Get the best of Consumer Goods research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Report Alerts

Get Email alerts about market research reports from industries and publishers of your interest: